Anavex Life Sciences Corp.

NasdaqGS:AVXL Stock Report

Market Cap: US$419.9m

Anavex Life Sciences Dividends and Buybacks

Dividend criteria checks 0/6

Anavex Life Sciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-2.2%

Buyback Yield

Total Shareholder Yield-2.2%
Future Dividend Yieldn/a
Dividend Growthn/a
Next dividend pay daten/a
Ex dividend daten/a
Dividend per sharen/a
Payout ration/a

Recent dividend and buyback updates

No updates

Recent updates

Anavex Life Sciences: Negative CHMP Decision Does Not Bode Well For Future Approval For Alzheimer's

Dec 03

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

May 21
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Anavex: Looking At Different Statistical Approaches Before EMA Opinion

Feb 14

The Misconceptions About Anavex Life Sciences' Blarcamesine Phase 2b/3 Trial In Alzheimer's Disease

Jan 10

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Dec 25
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Anavex Life Sciences: Why I Am Still Not Buying The Bull Thesis

Dec 24

Anavex: EU Approval Application Is A Precipitous Moment

Dec 08

Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease

Nov 11

Anavex: Understanding Their Latest Alzheimer's Data News With Caution

Nov 05

Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)

Oct 08

Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising

Jul 29

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Jul 17
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Apr 01
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Sep 19
Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

May 10
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

Jan 16
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if AVXL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AVXL's dividend payments have been increasing.

Dividend Yield vs Market

Anavex Life Sciences Dividend Yield vs Market
How does AVXL dividend yield compare to the market?
SegmentDividend Yield
Company (AVXL)n/a
Market Bottom 25% (US)1.4%
Market Top 25% (US)4.2%
Industry Average (Biotechs)2.2%
Analyst forecast (AVXL) (up to 3 years)n/a

Notable Dividend: Unable to evaluate AVXL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AVXL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate AVXL's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as AVXL has not reported any payouts.

Discover strong dividend paying companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/02 14:57
End of Day Share Price 2026/02/02 00:00
Earnings2025/09/30
Annual Earnings2025/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Anavex Life Sciences Corp. is covered by 10 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caroline PalomequeBerenberg
Yun ZhongBrean Capital
Jason KolbertD. Boral Capital LLC.